http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
포스터 전시 : 담도,췌장 ; 급성 비결석성 담낭염에 동반된 간문맥과 상장간막정맥 혈전증 1예
류성태 ( S. T. Ryu ),이진우 ( J. W. Lee ),이경오 ( K. O. Lee ),김화숙 ( W. S. Kim ),정석 ( S. Jung ),이돈행 ( D. H. Lee ),권계숙 ( G. S. Kwon ),김범수 ( P. S. Kim ),조현근 ( H. G. Cho ),김형길 ( H. G. Kim ),신용운 ( Y. W. Sin ),김영수 대한소화기학회 2002 대한소화기학회 춘계학술대회 Vol.2002 No.-
간문맥 또는 장간막정맥 혈전증의 원인은 원발성과 이차적 원인으로 Protein C, Protein S, Antithrombin Ⅲ 결핍 등의 과응고 상태, 복부외상, 문맥압 항진증, 복강내 악성종양, 골수증식성질환, 염증성 장질환, 그리고 췌장염, 복막염, 맹장염 등의 복강내 감염이 있다. 급성 담낭염에 의한 간문맥과 장간막정맥 혈전증은 극히 드물어 아직까지 국내에서 보고된바 없다. 저자들은 급성 비결석성 담낭염의 합병증으로 발생하여 항응고요법으로 호전
유병우(B.W. Ryu),한정만(J.M. Han),이동욱(D.W. Lee),이종달(J.D. Lee),이병희(B.H. Lee),최성욱(S.W. Choi),문건우(G.W. Moon) 전력전자학회 2009 전력전자학술대회 논문집 Vol.2009 No.1
최근 LCD 모니터, Note PC, 가정용 게임기, Mobile Phone, MP3 등의 소형 전자 제품의 사용이 증가함에 따라 이들 전자제품의 전원 공급에 필요한 다양한 AC/DC 어댑터가 요구된다. AC/DC 어댑터는 밀폐형의 구조를 가지므로, 열적인 문제 때문에 용량과 사이즈가 제한되어 왔다. 하지만 최근에는 소형전자제품의 용량이 점차 증가하고, 더불어 소비자의 휴대성 및 심미적 요구에 부응하기 위하여 소형 및 경량의 고밀도 AC/DC Adapter를 개발하여야 한다. 이를 위해서 높은 수준의 회로 설계 및 방열 기술이 필요하다. 본 논문에서는 Laptop PC에 적용되는 85W급 AC/DC Adapter용 고밀도전원을 개발하고 실험으로 검증하였다.
Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
Park, S R,Kim, H K,Kim, C G,Choi, I J,Lee, J S,Lee, J H,Ryu, K W,Kim, Y-W,Bae, J-M,Kim, N K Cancer Research UK 2008 The British journal of cancer Vol.98 No.8
We designed a phase I/II trial of S-1 combined with weekly docetaxel to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in metastatic gastric carcinoma (MGC). Patients with measurable disease received S-1 orally b.i.d. on days 1–14 and docetaxel intravenously on days 1 and 8 every 3 weeks. In phase I (n=30), each cohort received escalating doses of S-1 (30–45 mg m<SUP>−2</SUP> b.i.d.) and docetaxel (25–40 mg m<SUP>−2</SUP>); MTD was 45 mg m<SUP>−2</SUP> b.i.d. S-1/35 mg m<SUP>−2</SUP> docetaxel and RD was 40 mg m<SUP>−2</SUP> b.i.d. S-1/35 mg m<SUP>−2</SUP> docetaxel. Dose-limiting toxicities included grade 3 elevated liver enzymes, gastric perforation, grade 3 diarrhoea/fatigue, febrile neutropenia with grade 3 anorexia/fatigue, and neutropenic infection with grade 3 stomatitis/anorexia. In phase II (n=52), the overall response rate was 66.7% (95% confidence interval (CI): 53.8–79.6%) and the median time to progression and overall survival were 6.5 months (95% CI: 4.9–8.1) and 13.7 months (95% CI: 9.9–17.5), respectively. The most common grade 3/4 toxicity was neutropenia (29.4%), and febrile neutropenia/neutropenic infection occurred in 19.6% of patients. Non-haematological toxicities were generally mild. There was one treatment-related death due to pneumonitis. S-1 combined with weekly docetaxel is active in MGC with moderate toxicities.British Journal of Cancer (2008) 98, 1305–1311. doi:10.1038/sj.bjc.6604312 www.bjcancer.com Published online 25 March 2008
Park, S R,Kong, S-Y,Nam, B-H,Choi, I J,Kim, C G,Lee, J Y,Cho, S J,Kim, Y W,Ryu, K W,Lee, J H,Rhee, J,Park, Y-I,Kim, N K Nature Publishing Group 2011 The British journal of cancer Vol.104 No.7
<P><B>Background:</B></P><P>We evaluated the association between polymorphisms of cytochrome P450 2A6 (<I>CYP2A6</I>)/excision repair cross-complementation group 1 (<I>ERCC1</I>)/X-ray repair cross-complementing group 1(<I>XRCC1</I>) and treatment outcomes of metastatic gastric cancer (MGC) patients treated with S-1/cisplatin.</P><P><B>Methods:</B></P><P>Among MGC patients (<I>n</I>=108), who received S-1 (40 mg m<SUP>−2</SUP> b.i.d., days 1–14) and cisplatin (60 mg m<SUP>−2</SUP>, day 1) every 3 weeks, we analysed the wild-type allele (<I>W</I>) and variants (<I>V</I>) of <I>CYP2A6</I> (<I>*4</I>, <I>*7, *9, *10</I>), and the polymorphisms of <I>ERCC1</I> (rs11615, rs3212986) and <I>XRCC1</I> (rs25487).</P><P><B>Results:</B></P><P>Patients having fewer <I>CYP2A6</I> variants had better response rates (<I>W</I>/<I>W vs W</I>/<I>V</I> other than <I>*1/*4 vs V</I>/<I>V</I> or <I>*1/*4</I>=66.7 <I>vs</I> 58.3 <I>vs</I> 32.3% <I>P</I>=0.008), time to progression (TTP) (7.2 <I>vs</I> 6.1 <I>vs</I> 3.5 months, <I>P</I>=0.021), and overall survival (23.2 <I>vs</I> 15.4 <I>vs</I> 12.0 months, <I>P</I>=0.004). <I>ERCC1 19442C</I>><I>A</I> (rs3212986) was also associated with response rate (<I>C/C</I>, 46.7% <I>vs C/A</I>, 55.3% <I>vs A/A</I>, 87.5%) (<I>P</I>=0.048) and TTP (4.4 <I>vs</I> 7.6 <I>vs</I> 7.9 months) (<I>P</I>=0.012). Patients carrying both risk genotypes of <I>CYP2A6</I> (<I>V</I>/<I>V</I> or <I>1/*4</I>) and <I>ERCC1 19442C</I>><I>A</I> (<I>C/C</I>) <I>vs</I> those carrying none showed an adjusted odds ratio of 0.113 (<I>P</I>=0.004) for response, and adjusted hazard ratios of 3.748 (<I>P</I>=0.0001) for TTP and 2.961 (<I>P</I>=0.006) for death.</P><P><B>Conclusion:</B></P><P>Polymorphisms of <I>CYP2A6</I> and <I>ERCC1 19442C</I>><I>A</I> correlated with the efficacy of S-1/cisplatin.</P>
Park, J. S.,Kim, D. J.,Park, J. W.,Ryu, H. S.,Kim, K. W.,Wang, G. X.,Ahn, H. J. American Scientific Publishers 2012 Journal of Nanoscience and Nanotechnology Vol.12 No.7
<P>An elemental sulfur and multi-walled carbon nanotube (S-MWNT) composite was synthesized by dissolving sulfur in ammonium sulfides and then precipitating on MWNT. Morphology observation by scanning electron microscopy (SEM) confirmed that S-MWNT product was successfully prepared by incorporating sulfur into MWNT network. Without additional conducting material, the S-MWNT composite cathodes were prepared for electrochemical tests. The properties measured in discharge-charge cycling test showed that the composite had the initial discharge capacity of 1024 mAh g(-1), which is about 61% sulfur utilization. However, in the subsequent cycling, the capacities faded. To determine the reason of rapid capacity drop, S-MWNT composite cathodes were compared in the cycling tests with varying three kinds of electrolytes and the cathode was subjected to physical force by rolling. The changes in the cycle performances proved that the deterioration of S-MWNT composite cathodes was not related to the electrolytes but to physical bonding that may not maintain the conducting path between sulfur and MWNT.</P>
박창순(C. S. Park),안선응(S. E. Ahn),신완선(W. S. Shin),유진성(J. S. Ryu),박재우(J. W. Park),우문규(M. K. Woo) 한국산업경영시스템학회 2008 한국산업경영시스템학회지 Vol.31 No.2
Most organizations have recently put more emphasis on the improvement in service quality. This phenomenon could come from the recognition that service quality plays an essential role in enhancing organization"s business performance. Hence this paper presents a framework for improving such service quality. The presented framework involves the methodology for (ⅰ) developing service quality indices, (ⅱ) measuring and evaluating service quality, (ⅲ) analyzing the level of service quality, (ⅳ) constructing the quality improvement road map, (ⅴ) determining the quality improvement action plan. This methodology is intended to create self-sustaining improvement in service quality from the entire organization"s perspective. An illustration is also given.
Kim, K-p,Jang, G,Hong, Y S,Lim, H-S,Bae, K-s,Kim, H-S,Lee, S S,Shin, J-G,Lee, J-L,Ryu, M-H,Chang, H-M,Kang, Y-K,Kim, T W Nature Publishing Group 2011 The British journal of cancer Vol.104 No.4
<P><B>Background:</B></P><P>Advanced biliary cancer is often treated with fluoropyrimidine-based chemotherapy. In this study, we evaluated the efficacy and tolerability of a combination of S-1, an oral fluoropyrimidine prodrug, and oxaliplatin in patients with metastatic biliary cancer.</P><P><B>Methods:</B></P><P>Patients with histologically confirmed metastatic biliary cancer and no history of radiotherapy or chemotherapy were enrolled. Oxaliplatin was administered intravenously (130 mg m<SUP>−2</SUP>), followed by 14-day administration of oral S-1 (40 mg m<SUP>−2</SUP> twice daily) with a subsequent 7-day rest period every 21 days. Pharmacokinetic analysis of S-1 was performed at cycle 1. Patients were genotyped for <I>CYP2A6</I> polymorphisms (<SUP>*</SUP>1, <SUP>*</SUP>4, <SUP>*</SUP>7, <SUP>*</SUP>9 or <SUP>*</SUP>10), and pharmacokinetic and clinical parameters compared according to the <I>CYP2A6</I> genotype.</P><P><B>Results:</B></P><P>In total, 49 patients were evaluated, who received a median of four cycles. The overall response rate was 24.5%. Median progression-free and overall survival was 3.7 and 8.7 months, respectively. The most common haematological grade 3 out of 4 toxicity was neutropenia (14%), while non-hematological grade 3 out of 4 toxicities included anorexia (14%), nausea (12%), asthenia (10%), vomiting (10%), and diarrhoea (4%). Biotransformation of S-1 (AUC<SUB>0−24 h</SUB> of 5-fluorouracil/AUC<SUB>0−24 h</SUB> of tegafur) was 1.85-fold higher for the <I>*1/*1</I> group than for the other groups (90% confidence interval 1.37–2.49). Diarrhoea (<I>P</I>=0.0740), neutropenia (<I>P</I>=0.396), and clinical efficacy (response rate, <I>P</I>=0.583; PFS, <I>P</I>=0.916) were not significantly associated with <I>CYP2A6</I> genotype, despite differences in 5-FU exposure.</P><P><B>Conclusion:</B></P><P>The combination of S-1 and oxaliplatin appears to be active and well tolerated in patients with metastatic biliary cancer, and thus is feasible as a therapeutic modality. <I>CYP2A6</I> genotypes are associated with differences in the biotransformation of S-1. However, the impact of the <I>CYP2A6</I> polymorphism on variations in clinical efficacy or toxicity requires further evaluation.</P>